$1.61
-0.09 (-5.29%)
Open$1.72
Previous Close$1.70
Day High$1.72
Day Low$1.60
52W High$3.54
52W Low$1.38
Volume—
Avg Volume1.05M
Market Cap159.68M
P/E Ratio—
EPS$-1.42
SectorBiotechnology
Analyst Ratings
Strong Buy
14 analysts
Price Target
+401.9% upside
Current
$1.61
$1.61
Target
$8.08
$8.08
$6.79
$8.08 avg
$13.52
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 11.85M | 12.74M | 54.83M |
| Net Income | -157,310,324 | -152,153,994 | 10.00M |
| Profit Margin | -1,327.4% | -1,261.0% | 18.2% |
| EBITDA | -163,400,011 | -166,824,299 | 16.80M |
| Free Cash Flow | — | — | 9.93M |
| Rev Growth | -7.0% | -7.0% | -2.4% |
| Debt/Equity | — | — | 0.64 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 70.2 | 443.23B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.8 | 225.90B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 169.87B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 30.7 | 135.24B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 19.0 | 82.16B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 37.6 | 30.39B |